All In Biotech

Drug Trial Radar · NCT02308527

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Jul 2013

Primary completion

Aug 1, 2021

Study completion Feb 18, 2026

Sponsor

Lead sponsor
University of BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research UK; Roche Pharma AG; Imagine for Margo; EUSA Pharma, Inc.
First posted
Dec 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or Topotecan-Temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma. Also, to investigate whether the addition of Irinotecan or Topotecan to Temozolomide increases the activity of chemotherapy.The primary objective of the study is the best response (Complete Response or Partial Response) while trial treatment, within 18 or 24 weeks depending on the arm of the trial the participant is randomised to. Secondary endpoints are assessing the side effects, the length of time before progression (Progression Free Survival) and overall survival (OS). This trial will address two important questions: * does targeting blood vessel development using bevacizumab, (a monoclonal antibody against the Vascular Endothelial Growth Factor (VEGF)), add to the effect on a tumour when used with existing chemotherapy, compared to the effect of the existing chemotherapy alone (temozolomide)? NOTE- This question has been completed. * does the addition of a second chemotherapy drug (irinotecan or topotecan) increase the effect on a tumour compared to the effect of one alone (temozolomide) NOTE - This question has been completed. * does the addition of dinutuximab beta added to a backbone chemotherapy (temozolomide or temozolomide + topotecan) increase the effect of backbone alone. Patients aged 1-21 years of age with relapsed or refractory high-risk neuroblastoma are randomised to one of two treatment arms: temozolomide-topotecan (TTo) or dinutuximab beta-temozolomide-topotecan (dBTTo). Temozolomide (T), irinotecan-temozolomide (IT), bevacizumab-T (BT), BIT (bevacizumab-IT), bevacizumab-temozolomide-topotecan (BTTo) and dinutuximab beta-temozolomide (dBT) are now closed to recruitment.

Conditions

  • Neuroblastoma

Interventions

  • BevacizumabDrug

    10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression

  • TemozolomideDrug

    200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

  • TemozolomideDrug

    100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression

  • IrinotecanDrug

    50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression

  • BevacizumabDrug

    15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression

  • TopotecanDrug

    0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression

  • TemozolomideDrug

    150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

  • Dinutuximab BetaDrug

    10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression

  • CyclophosphamideDrug

    250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best response (Complete Response or Partial Response) while on trial treatment, within 18 or 24 weeks depending on the arm of the trial participant is randomised to.Time frame: Within 18 or 24 weeks depending on the arm of the trial the participant is randomised to.
  2. For the bevacizumab part 2 only; Progression-free survival (PFS)Time frame: Assessment will be after 30 days after treatment or end of trial

Locations

10 sites in 10 countries. Site status is shown where the registry gives one.

  • St Anna Children's Hospital and CCRI/Studies and Statistics

    Vienna, Austria

  • University Hospital

    Ghent, Belgium

  • University Hospital Rigshospitalet

    Copenhagen, Denmark

  • Hopital des Enfants

    Toulouse, France

  • Our Ladys Children's Hospital Dublin

    Dublin, Ireland

  • Ospedale Pediatrico Bambino Gseu

    Rome, Italy

  • Natasha van Eijkelenburg

    Utrecht, Netherlands

  • Instituto de Investigacion Sanitaria

    Valencia, Spain

  • Swiss Paediatric Oncology Group

    Bern, Switzerland

  • The Royal Marsden NHS Foundation Trust and Institute of Cancer Research

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.